Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Licenses Ex-China Rights for Cancer Molecule to Merck Serono

publication date: May 31, 2013
BeiGene, a Beijing biopharma startup, has out-licensed the ex-China rights for a pre-clinical cancer drug to Merck Serono in a $233 million deal. To date, BeiGene has been in the news for acquiring China rights to western-developed drugs. But in this case, BeiGene discovered the second-generation BRAF inhibitor itself. According to BeiGene, the compound could begin clinical trials in China later this year. That means BeiGene, which was founded in 2010, will have completed China preclinical development in the remarkably short time of three years. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital